Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Immutep to Host Key Opinion Leader Call | ||||||||||||||||||||||||||
| By: Nasdaq / GlobeNewswire - 24 Jun 2019 | Back to overview list |
|||||||||||||||||||||||||
Presentations on Novel Immuno-Oncology Therapy (eftilagimod alpha) in Metastatic Breast Cancer and Other Settings NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, will host a key opinion leader (KOL) call on novel immuno-oncology therapy (eftilagimod alpha) in the treatment of metastatic breast cancer and other settings on Wednesday, June 26 at 11.00am EDT / 8.00am PDT (Thursday, June 27 at 1.00am AEST). The call will feature overview presentations by KOLs: Dr. Luc Dirix, MD PhD, from the AZ Sint-Augustinus Hospital in Antwerp, Belgium, and Prof. Salah-Eddin Al-Batran, MD, from the Institute of Clinical Research in Frankfurt, Germany. They will discuss their clinical experience with eftilagimod alpha in AIPAC (metastatic breast cancer) and INSIGHT (exploratory investigator-initiated trial) as well as the current treatment landscape and unmet medical needs, specifically in HER2-negative / HR positive metastatic breast cancer. Immutep’s Chief Scientific Officer and Chief Medical Officer, Frederic Triebel, MD PhD, will provide a brief overview of eftilagimod alpha's unique mechanism-of-action, ongoing eftilagimod alpha clinical studies and a LAG-3 update. All presenters will be available at the end of the event to answer questions.
A replay of the KOL call will be made available on the Company’s website following the event, at www.immutep.com/investors-media/presentations. KOL biographies Prof. Al-Batran is the Medical Director at the Institute of Clinical Cancer Research in Frankfurt, Germany. As a hematologist and oncologist, he is on the Board of the University Cancer Centre in Frankfurt, and Task Force director for Phase I/II Trials. He is a member of the German Society of Clinical Oncology, the American Society of Clinical Oncology, and the European Organization for Research and Treatment of Cancer. About Eftilagimod Alpha (LAG-3Ig) About Immutep Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada) referred to as TACTI-002 (Two ACTive Immunotherapies) to evaluate a combination of efti with KEYTRUDA® (pembrolizumab) in several different solid tumors (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc., referred to as INSIGHT-004, to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869). Further information can be found on the Company’s website www.immutep.com or by contacting: U.S. Investors: Australian Investors/Media: U.S. Media: |
||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||
 | Back to overview list | |||||||||||||||||||||||||